Download PDF
CC BY-NC-ND 4.0 · Horm Metab Res 2023; 55(03): 212-221
DOI: 10.1055/a-2007-2631
Original Article: Endocrine Research

Common Key Genes in Differentiating Parathyroid Adenoma From Thyroid Adenoma

Yanbin Lin
1   Department of Nephrology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
,
Jinxuan He
1   Department of Nephrology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
,
Zhixiang Mou
1   Department of Nephrology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
,
Yuchen Tian
1   Department of Nephrology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
,
Huiting Chen
1   Department of Nephrology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
,
Tianjun Guan
1   Department of Nephrology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
,
Lan Chen
1   Department of Nephrology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
› Author Affiliations
Funding Information Natural Science Foundation of Fujian Province — http://dx.doi. org/10.13039/501100003392; 2021J011330; Natural Science Foundation of Xiamen City — http://dx.doi.org/10.13039/100016808; 3502Z20194016
› Further Information
Also available at
  Permissions and Reprints

Corrected by:

Correction: Common Key Genes in Differentiating Parathyroid Adenoma From Thyroid AdenomaHorm Metab Res 2023; 55(03): e1-e1
DOI: 10.1055/a-2055-1802

Abstract

Recent studies have demonstrated the close relationship between parathyroid adenoma (PA) and thyroid follicular adenoma (FTA). However, the underlying pathogenesis remains unknown. This study focused on exploring common pathogenic genes, as well as the pathogenesis of these two diseases, through bioinformatics methods. This work obtained PA and FTA datasets from the Integrated Gene Expression Database to identify the common differentially expressed genes (DEGs) of two diseases. The functions of the genes were investigated by GO and KEGG enrichment. The program CytoHubba was used to select the hub genes, while receiver operating characteristic curves were plotted to evaluate the predictive significance of the hub genes. The DGIbd database was used to identify gene-targeted drugs. This work detected a total of 77 DEGs. Enrichment analysis demonstrated that DEGs had activities of 3′,5′-cyclic AMP, and nucleotide phosphodiesterases and were associated with cell proliferation. NOS1, VWF, TGFBR2, CAV1, and MAPK1 were identified as hub genes after verification. The area under the curve of PA and FTA was>0.7, and the hub genes participated in the Relaxin Signaling Pathway, focal adhesion, and other pathways. The construction of the mRNA-miRNA interaction network yielded 11 important miRNAs, while gene-targeting drug prediction identified four targeted drugs with possible effects. This bioinformatics study demonstrated that cell proliferation and tumor suppression and the hub genes co-occurring in PA and FTA, have important effects on the occurrence and progression of two diseases, which make them potential diagnostic biomarkers and therapeutic targets.

Key words

parathyroid adenoma - thyroid adenoma -  thyroid - key genes - bioinformatics - drug prediction


Publication History

Received: 23 October 2022

Accepted after revision: 15 December 2022

Accepted Manuscript online:
04 January 2023

Article published online:
27 February 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Shi YH, Dixit J, Koh D. et al. Functional and genetic studies of isolated cells from parathyroid tumors reveal the complex pathogenesis of parathyroid neoplasia. Proc Natl Acad Sci U S A 2014; 111: 3092-3097
    CrossrefPubMedSearch in Google Scholar
  • 2 Ishii H, Mihai R, Watkinson JC. et al. Systematic review of cure and recurrence rates following minimally invasive parathyroidectomy. BJS Open 2018; 2: 364-370
    CrossrefPubMedSearch in Google Scholar
  • 3 Sala TD, Muresan S, Roman R. et al. Hypercalcaemic crisis due to primary hyperparathyroidism: report of two cases. J Crit Care Med (Targu Mures) 2019; 5: 34-39
    CrossrefPubMedSearch in Google Scholar
  • 4 Theurer SSU, Lorenz K, Dralle H. et al. Ektopes Gewebe der Schilddrüse und der Nebenschilddrüsen Ectopic tissue of the thyroid gland and the parathyroid glands. Pathologe 2018; 39: 379-389
    CrossrefPubMedSearch in Google Scholar
  • 5 Rodrigo JP, Hernandez-Prera JC, Randolph GW. et al. Parathyroid cancer: an update. Cancer Treat Rev 2020; 86: 102012
    CrossrefPubMedSearch in Google Scholar
  • 6 Verdelli C, Morotti A, Tavanti GS. et al. The core stem genes SOX2, POU5F1/OCT4, and NANOG are expressed in human parathyroid tumors and modulated by MEN1, YAP1, and beta-catenin pathways activation. Biomedicines 2021; 9: 637
    CrossrefPubMedSearch in Google Scholar
  • 7 Papanikolaou A, Katsamakas M, Boudina M, Pamporaki C. et al. Intrathyroidal parathyroid adenoma mimicking thyroid cancer. Endocrine Journal 2020; 67: 639-643
    CrossrefPubMedSearch in Google Scholar
  • 8 Saljo K, Thornell A, Jin C. et al. Characterization of glycosphingolipids in the human parathyroid and thyroid glands. Int J Mol Sci 2021; 22: 7044
    CrossrefPubMedSearch in Google Scholar
  • 9 Erickson LA, Mete O, Juhlin CC. et al. Overview of the 2022 WHO classification of parathyroid tumors. Endocr Pathol 2022; 33: 64-89
    CrossrefPubMedSearch in Google Scholar
  • 10 Michael P, Bannon MD, Van Heerden MB. et al. The relationship between primary hyperparathyroidism and diabetes mellitus. Ann Surg 1988; 207: 430-433
    CrossrefPubMedSearch in Google Scholar
  • 11 Paloyan Walker RKE, Gopalsami C, Bassali J. et al. Hyperparathyroidism associated with a chronic hypothyroid state. Laryngoscope 1997; 107: 903-909
    CrossrefPubMedSearch in Google Scholar
  • 12 Yavropoulou MP, Poulios C, Michalopoulos N. et al. A role for circular non-coding RNAs in the pathogenesis of sporadic parathyroid adenomas and the impact of gender-specific epigenetic regulation. Cells 2018; 8: 15
    CrossrefPubMedSearch in Google Scholar
  • 13 Verdelli C, Forno I, Vaira V. et al. Epigenetic alterations in human parathyroid tumors. Endocrine 2015; 49: 324-332
    CrossrefPubMedSearch in Google Scholar
  • 14 Vaira V, Elli F, Forno I. et al. The microRNA cluster C19MC is deregulated in parathyroid tumours. J Mol Endocrinol 2012; 49: 115-124
    CrossrefPubMedSearch in Google Scholar
  • 15 Hu Y, Zhang X, Cui M. et al. Circular RNA profile of parathyroid neoplasms: analysis of co-expression networks of circular RNAs and mRNAs. RNA Biol 2019; 16: 1228-1236
    CrossrefPubMedSearch in Google Scholar
  • 16 Li Q, Li Y, Sun X. et al. Genomic analysis of abnormal DNAM methylation in parathyroid tumors. Int J Endocrinol 2022; 4995196
    PubMedSearch in Google Scholar
  • 17 The Gene Ontology C The gene ontology resource: 20 years and still GOing strong. Nucleic Acids Res 2019; 47: D330-D338
    CrossrefPubMedSearch in Google Scholar
  • 18 Kanehisa M, Furumichi M, Sato Y. et al. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res 2021; 49: D545-D551
    CrossrefPubMedSearch in Google Scholar
  • 19 Szklarczyk D, Gable AL, Lyon D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019; 47: D607-D613
    CrossrefPubMedSearch in Google Scholar
  • 20 Otasek D, Morris JH, Boucas J. et al. Cytoscape automation: empowering workflow-based network analysis. Genome Biol 2019; 20: 185
    CrossrefPubMedSearch in Google Scholar
  • 21 Zhou G, Soufan O, Ewald J. et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res 2019; 47: W234-W241
    CrossrefPubMedSearch in Google Scholar
  • 22 Freshour SL, Kiwala S, Cotto KC. et al. Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res 2021; 49: D1144-D1151
    CrossrefPubMedSearch in Google Scholar
  • 23 Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521-534
    CrossrefPubMedSearch in Google Scholar
  • 24 Li X, Zou Z, Tang J. et al. NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells. Oncol Lett 2019; 17: 1595-1602
    PubMedSearch in Google Scholar
  • 25 Wang Q, Ye S, Chen X. et al. Mitochondrial NOS1 suppresses apoptosis in colon cancer cells through increasing SIRT3 activity. Biochem Biophys Res Commun 2019; 515: 517-523
    CrossrefPubMedSearch in Google Scholar
  • 26 Brait M, Loyo M, Rosenbaum E. et al. Correlation between BRAF mutation and promoter methylation of TIMP3, RARbeta2 and RASSF1A in thyroid cancer. Epigenetics 2012; 7: 710-719
    CrossrefPubMedSearch in Google Scholar
  • 27 Kong QFLB, Wang B, Zhang XP. et al. Association of von Willebrand factor (vWF) expression with lymph node metastasis and hemodynamics in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci 2020; 24: 2564-2571
    PubMedSearch in Google Scholar
  • 28 Mishra SMV, Kumar S. Ankita et al. Clinical management and therapeutic strategies for the thyroid-associated ophthalmopathy: current and future perspectives. Curr Eye Res 2020; 45: 1325-1341
    CrossrefPubMedSearch in Google Scholar
  • 29 Peres KC, Teodoro L, Amaral LHP. et al. Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis. Arch Endocrinol Metab 2021; 65: 172-184
    PubMedSearch in Google Scholar
  • 30 Kardalas E, Sakkas E, Ruchala M. et al. The role of transforming growth factor beta in thyroid autoimmunity: current knowledge and future perspectives. Rev Endocr Metab Disord 2022; 23: 47
    PubMedSearch in Google Scholar
  • 31 Imam N, Alam A, Siddiqui MF. et al. Identification of key regulators in parathyroid adenoma using an integrative gene network analysis. Bioinformation 2020; 16: 910-922
    CrossrefPubMedSearch in Google Scholar
  • 32 Shankar J, Wiseman SM, Meng F. et al. Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer. J Pathol 2012; 228: 56-66
    CrossrefPubMedSearch in Google Scholar
  • 33 Chai YJ, Chae H, Kim K. et al. Comparative gene expression profiles in parathyroid adenoma and normal parathyroid tissue. J Clin Med 2019; 8: 297
    CrossrefPubMedSearch in Google Scholar
  • 34 Nie FR, Li QX, Wei HF. et al. miR-326 inhibits the progression of papillary thyroid carcinoma by targeting MAPK1 and ERBB4. Neoplasma 2020; 67: 604-613
    CrossrefPubMedSearch in Google Scholar
  • 35 Chen H, Li Q, Yi R. et al. CircRNA casein kinase 1 gamma 1 (circ-CSNK1G1) plays carcinogenic effects in thyroid cancer by acting as miR-149-5p sponge and relieving the suppression of miR-149-5p on mitogen-activated protein kinase 1 (MAPK1). J Clin Lab Anal 2022; 36: e24188
    CrossrefPubMedSearch in Google Scholar
  • 36 Blake JF, Burkard M, Chan J. et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-y l)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor in early clinical development. J Med Chem 2016; 59: 5650-5660
    CrossrefPubMedSearch in Google Scholar
  • 37 Zhu J, Wang J, Wang X. et al. Prediction of drug efficacy from transcriptional profiles with deep learning. Nat Biotechnol 2021; 39: 1444-1452
    CrossrefPubMedSearch in Google Scholar
  • 38 Janardhan HP, Dresser K, Hutchinson L. et al. Pathological MAPK activation-mediated lymphatic basement membrane disruption causes lymphangiectasia that is treatable with ravoxertinib. JCI Insight 2022; 7: e153033
    CrossrefPubMedSearch in Google Scholar